Trial Profile
A Single-Center, Randomized, Double-Blind, Placebo Controlled, Multiple-Dose, Dose Escalation Study to Evaluate the Safety/Tolerability and Pharmacokinetics of AD 6626 Administered Orally to Normal, Healthy Volunteers
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 18 Nov 2019
Price :
$35
*
At a glance
- Drugs AD 6626 (Primary)
- Indications Alcoholism; Fanconi's anaemia
- Focus Adverse reactions
- Sponsors ALDEA Pharmaceuticals
- 15 Nov 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 20 Jul 2015 New trial record